Document is current
Any future updates will be listed below
-
Authors
Eweje, Feyisayo https://orcid.org/0000-0001-7936-5384
Ibrahim, Vanessa https://orcid.org/0009-0009-0354-6221
Shajii, Aram
Walsh, Michelle L. https://orcid.org/0000-0001-5563-5829
Ahmad, Kiran
Alrefai, Assma https://orcid.org/0009-0006-8904-7754
Miyasato, Dominie
Davis, Jessie R.
Ham, Hyunok
Li, Kaicheng
Roehrl, Michael https://orcid.org/0000-0003-4892-1098
Haller, Carolyn A.
Liu, David R.
Chen, Jiaxuan https://orcid.org/0000-0001-5801-9052
Chaikof, Elliot L. https://orcid.org/0000-0001-6184-4571
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (UG3AI15055, UH3AI150551, 5T32GM007753-42, 5T32GM144273-02, UG3AI15055, UH3AI150551, UG3AI15055, UH3AI150551, UG3AI15055, UH3AI150551, UG3AI15055, UH3AI150551)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (F31HL167533)
Harvard College Research Program
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 14 August 2024
Accepted: 1 April 2025
First Online: 15 May 2025
Competing interests
: F.E., J.C. and E.L.C. are inventors on a pending patent related to this work filed by the Beth Israel Deaconess Medical Center (PCT/US2024/038614). D.R.L. is a consultant and equity holder of Nvelop Medicine, Prime Medicine, Beam Therapeutics, Pairwise Plants and Chroma Medicine, companies that use or deliver gene editing or genome engineering agents. The other authors declare no competing interests.
